AAVantgarde Bio

Pre-clinical

Milan, ItalyFounded 2019aavantgarde.com

Develops novel AAV vectors for gene therapy targeting neurological and rare diseases.

Market Cap

Private

Pipeline

—

Patents

—

Publications

—

Private Company

Total funding raised: $233.5M

Develops novel AAV vectors for gene therapy targeting neurological and rare diseases.

Drug DeliveryRNA & Gene TherapyViral Technology

Total raised:$233.5M

Series B$141MUndisclosedNov 3, 2025

Series A$50MNovartis Venture FundNov 15, 2023

Series A$30MSofinnova PartnersNov 15, 2023

Seed$4.5MSofinnova PartnersJun 15, 2022